Today: 21 May 2026
Browse Category

NASDAQ:SEMR 19 November 2025 - 31 December 2025

Reddit stock slips late as insider sale disclosure and AI-search thesis stay in focus

Reddit stock slips late as insider sale disclosure and AI-search thesis stay in focus

Reddit shares fell 1.5% to $229.89 in late Wednesday trading after a regulatory filing showed CTO Christopher Slowe sold 14,000 shares last week under a pre-arranged plan. Needham reiterated a Buy rating, citing Reddit’s frequent citations in AI-generated answers as a key factor for valuation. Reddit’s market cap stood at about $43 billion. U.S. stocks were broadly lower ahead of the New Year’s holiday.
31 December 2025
·
Adobe (ADBE) Stock: 7 Things to Know Before the Market Opens on November 17, 2025

Adobe News Today (November 20, 2025): $1.9 Billion Semrush Deal, HUMAIN AI Partnership, and Market Reaction

Adobe announced a $1.9 billion all-cash deal to acquire Semrush, offering $12 per share—about 78% above Semrush’s last closing price. The company also signed a global AI partnership with Saudi-backed HUMAIN to develop Arabic-first generative models. Investors are reassessing Adobe’s outlook as the company shifts its AI and marketing strategy.
20 November 2025
···
Adobe (ADBE) Stock: 7 Things to Know Before the Market Opens on November 17, 2025

Adobe Stock Today (Nov. 19, 2025): $1.9 Billion Semrush Deal and New AI Pact Put ADBE in Focus

Adobe shares closed at $318 on Nov. 19, 2025, just above their 52-week low, down more than 2% despite announcing a $1.9 billion all-cash acquisition of Semrush at a 75% premium. The company also unveiled a new AI partnership in the Middle East with Humain and Qualcomm. William Blair raised its earnings estimates. Adobe stock is down 29% year-to-date.
19 November 2025
··

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Go toTop